ArticleOxford medical case reports2025
A case report of cutaneous Langerhans cell Histiocytosis in an infant: a therapeutic challenge.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Langerhans Cell Histiocytosis (LCH) is a rare clonal disorder of immature CD1a-positive dendritic cells, most commonly affecting children, with peak incidence between ages 1 and 3. This report presents a unique case of multifocal cutaneous LCH with cervical lymphadenopathy in a 7-month-old infant. The patient exhibited an unusual pattern of treatment resistance, failing to respond adequately to corticosteroids and vinblastine-prednisone, before achieving remission with methotrexate. This highlights the therapeutic challenges in managing refractory pediatric LCH and the need for alternative treatment approaches in such cases. This case emphasizes the importance of early diagnosis, tailored treatment regimens, and the potential utility of methotrexate in refractory cases. Comprehensive evaluation and multidisciplinary care are critical for managing this rare disease and minimizing its impact on quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.